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Background
Heart failure (HF) is a major public health
problem and is more common in the black
population. It affects approximately 3% of all
adult black Americans. Black patients develop
HF symptoms at an earlier age than non-black
patients. This may be due to the fact that black
patients are more likely to have hypertension and
diabetes than non-black patients. They more
frequently exhibit sodium retention, ventricular
hypertrophy, and vascular injury.
When
diagnosed, HF progresses more rapidly in black
than in white patients, as evidenced by a higher
risk of initial and recurrent hospitalization and
death.1
In the U. S. the prevalence of high blood
pressure (HBP) in African Americans is among
the highest in the world. They develop HBP
earlier in life and have higher average blood
pressures. Blacks have a 1.3 times greater rate of
nonfatal stroke, a 1.8 times greater rate of fatal
stroke, a 1.5 times greater rate of heart disease
death, and a 4.2 times greater rate of end-stage
renal disease than whites.2
Because racial minorities with HF are underrepresented in HF clinical trials of new drugs,
little is known about their response to medications
used
in
the
management
of
HF.
Recommendations for management of HF call for
control of systolic and diastolic hypertension.1
Most African Americans require combination
antihypertensive therapy to reach appropriate
blood pressure levels. The Hypertension in
African Americans Working (HAAW) Group’s
consensus statement suggests the combination of
agents to achieve target blood pressure when
required.
Combinations
include
betablocker/diuretic, angiotensin-converting enzyme
inhibitor (ACEI)/diuretic, ACEI/calcium-channel
blocker (CCB), or angiotensin-receptor blocker
(ARB)/diuretic dual therapies.3

The African-American Heart Failure Trial (AHeFT) suggests possible new combinations using
older drugs.4

Citation
Taylor AL, Ziesche S, Yancy C. et al.
Combination of isosorbide dinitrate and
hydralazine in blacks with heart failure. N Engl J
Med 2004;351:2049-57.

Methods
This study was a randomized, placebocontrolled, double-blind trial of 1,050 black
patients at least 18 years of age or older. These
self-identified African Americans had New York
Heart Association class III or IV heart failure with
dilated ventricles. All had a baseline mean
ejection fraction of 24% and were already
receiving standard therapy for heart failure.
Patients were randomly assigned to receive fixed
doses of isosorbide dinitrate (20 to 40 mg) plus
hydralazine (37.5 to 75 mg) orally three times
daily or placebo three times daily. In addition all
participants continued their standard heart failure
therapy. Standard therapy included diuretics,
ACEIs, ARBs, beta-blockers, carvedilol, digoxin,
or spironolactone. Stratification into groups was
based on use or nonuse of beta-blockers.
The study primary end point was a composite
score of weighted values combining death from
any cause, a first hospitalization for heart failure,
and change in the quality of life. Individual
scores could range from +2 (positive outcome) to
-6 (negative outcome). Patients were followed for
18 months.

Results
There were 518 patients that received
isosorbide dinitrate combined with hydralazine
compared with 532 placebo recipients. The
primary composite score was -0.1 +1.9 in the
More. . .
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treatment group compared with -0.5 +2.0 in the
placebo group (P=0.01) Individual endpoints
were 43% reduction in the rate of death from any
cause (hazard ratio, 0.57, P = 0.01), 33% relative
reduction in the rate of first hospitalization for
heart failure (16.4% vs. 22.4%, P= 0.001), and
improvement in the quality of life (change in
score, -5.6 +20.6 vs. -2.7 +21.2, with lower scores
indicating better quality of life, P= 0.02, range of
possible values, 0 to 105).
The trial was stopped after a ten month mean
duration of follow-up when survival analysis
revealed a significantly higher mortality rate in
the placebo group than in the treatment group
(10.2% vs. 6.2%, P=0.02).

Author Conclusions
Isosorbide dinitrate plus hydralazine in a fixed
dosage combined with existing standard heart
failure therapy was beneficial and increased
survival in black heart failure patients.

Commentary
The mortality benefit of combined isosorbide
dinitrate with hydralazine was described in an
earlier study of Veterans Administration male
patients already receiving digoxin and diuretics
(Vasodilator-Heart Failure Trial (V-HeFT I). This
randomized, placebo-controlled, double-blind
study identified a 36% mortality-risk reduction by
three years in the trial group treated with
isosorbide plus hydralazine (I-H), compared with
a prazosin-treatment group, and a placebotreatment group. The majority of patients in this
trial were non-African American; however the
greatest benefit was shown in the African
American I-H-treated group.5
Studies of vasodilatory drug effects in African
Americans have shown a reduced response to
Isosorbide
nitric oxide-mediated therapies.6,7
dinitrate stimulates the nitric oxide pathway and
hydralazine has antioxidant properties that inhibit
superoxide synthesis. The combined effects of
these two agents may help restore the balance of
nitric oxide and superoxide synthesis in African
Americans by dilating both arteries and veins.8
Other antihypertensive agents have been
identified as less effective in blacks. Betablockers and ACEIs, when administered as
monotherapy, were less effective in blood
pressure-lowering efficacy for black as compared

with white patients.3 Enalapril (Vasotec) is an
example of an ACEI found to have less
antihypertensive effect in black patients than in
non-blacks.9 In addition, it should be noted that
black patients receiving ACEIs have been
reported to have a higher incidence of angioedema
compared to non-blacks. The African-American
Study of Kidney Disease and Hypertension Study
Group identified the CCB, amlodipine (Norvasc),
as less renoprotective compared with the ACEI,
ramipril (Altace), in blacks with hypertensive
renal insufficiency.10 The antihypertensive effect
of the ARB, losartan (Cozaar), is somewhat less
in black patients.11
Despite these differences, all antihypertensive
drug classes are associated with blood pressure
lowering efficacy and improved outcomes in
blacks as well as non-blacks.3
A new drug application has been filed with the
FDA by NitroMed Inc. for a combination product
containing isosorbide dinitrate and hydralazine.
The product BiDil will be a fixed-dose oral
combination. It will be indicated for the treatment
of heart failure in African Americans. Product
launch is expected in 2005.12
As demonstrated in this study by Taylor et al
the addition of isosorbide dinitrate plus
hydralazine as a fixed-dose combination with
standard heart failure therapy is efficacious and
increases survival in black patients [Evidence
level A; high-quality RCT].4

Users of this document are cautioned to use their own
professional judgment and consult any other necessary
or appropriate sources prior to making clinical
judgments based on the content of this document. Our
editors have researched the information with input
from experts, government agencies, and national
organizations. Information and Internet links in this
article were current as of the date of publication.

More. . .
Copyright © 2005 by Therapeutic Research Center
Pharmacist’s Letter / Prescriber’s Letter ~ P.O. Box 8190, Stockton, CA 95208 ~ Phone: 209-472-2240 ~ Fax: 209-472-2249
www.pharmacistsletter.com ~ www.prescribersletter.com

(Detail-Document #210105: Page 3 of 3)

Levels of Evidence
In accordance with the trend towards Evidence-Based
Medicine, we are citing the LEVEL OF EVIDENCE
for the statements we publish.
Level
A

B

C
D

Definition
High-quality randomized controlled trial (RCT)
High-quality meta-analysis (quantitative
systematic review)
Nonrandomized clinical trial
Nonquantitative systematic review
Lower quality RCT
Clinical cohort study
Case-control study
Historical control
Epidemiologic study
Consensus
Expert opinion
Anecdotal evidence
In vitro or animal study

Adapted from Siwek J, et al. How to write an evidence-based
clinical review article. Am Fam Physician 2002;65:251-8.
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